Anixa Biosciences is a biotechnology company developing cancer therapies and vaccines targeting large unmet medical needs across oncology, particularly in ovarian, breast, lung, colon, and prostate cancers. The company's pipeline includes a modified CAR-T cell therapy (lira-cel) targeting ovarian cancer cells expressing FSH-Receptor, breast and ovarian cancer vaccines leveraging retired-protein technology licensed from Cleveland Clinic, and a discovery program to identify additional protein targets for common malignancies. The company generates no revenue from its therapeutic programs but historically derived income from technology licensing and patent sales; it pursues a business model of eventually licensing developed therapies to large pharmaceutical companies with manufacturing and commercial capabilities, with profitability dependent on positive clinical results and successful licensing transactions that may require several years to materialize.